Prostate cancer and advanced solid tumors
Clinical research includes metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, biochemically recurrent prostate cancer, and broader advanced solid tumors. The portfolio also covers PSMA-expressing disease and hepatocellular carcinoma, with interest in tumor control and disease progression across advanced oncology settings.
- PSMA-targeted prostate cancer
- metastatic hormone-sensitive prostate cancer
- hepatocellular carcinoma
- advanced solid tumors
Additional activity extends to radionuclide therapy and androgen deprivation therapy in prostate cancer, reflecting sustained involvement in treatment areas linked to advanced genitourinary malignancies.
Precision oncology and molecularly defined tumors
Research activity includes cancers characterized by actionable alterations such as NTRK fusions and HER2 mutations. The sponsor also funds studies in solid tumors harboring NTRK fusion and solid tumors with HER2 mutation, alongside pediatric and adult oncology populations.
- NTRK fusion-positive cancers
- HER2-mutated solid tumors
- pediatric advanced cancer
- molecularly selected oncology
These studies place emphasis on biomarker-defined tumor subsets across oncology, including both systemic disease and central nervous system involvement.
Menopause-related symptoms and women’s health
The sponsor supports clinical research in vasomotor symptoms associated with menopause and adjuvant endocrine therapy, as well as sleep disturbances associated with menopause. These trials include populations of women with, or at high risk for, hormone receptor-positive breast cancer.
- vasomotor symptoms
- sleep disturbances
- menopause
- hormone receptor-positive breast cancer
Interest in this area centers on symptom burden linked to hormonal change and cancer-related endocrine treatment.
Cardiovascular and rare disease research
Clinical studies also address transthyretin amyloid cardiomyopathy and severe hemophilia A. These programs span cardiomyopathy associated with amyloid deposition and inherited bleeding disorders requiring factor VIII replacement support.
- transthyretin amyloid cardiomyopathy
- severe hemophilia A
- factor VIII deficiency
- rare cardiovascular disease
This area reflects therapeutic interest in chronic conditions with substantial unmet medical need.
